Funding for this research was provided by:
National Cancer Institute (R01 CA258239)
Article History
Accepted: 3 December 2023
First Online: 27 December 2023
Declarations
:
: This work was supported by the NIH grant R01 CA258239 (Galanis, PI).
: E.G. has received honoraria for advisory board participation from Kiyatec, Inc. (personal compensation), Boston Scientific for Data and Safety Monitoring Committee, Servier Pharmaceuticals for Advisory Board, and Karyopharm Therapeutics, Inc. for data safety and -onitoring board participation (compensation to employer). Her institution has received grant funding from Servier Pharmaceuticals LLC (formerly Agios Pharmaceuticals, Inc.), Celgene, MedImmune, Inc., and Denovo Biopharma. G.M.S. and I.I. report no conflicts of interest.
: Not applicable.
: Not applicable.
: GMS and II reviewed the literature and composed the first draft. EG reviewed and edited the manuscript.
: Not applicable.
: Not applicable.